Background: Diabetes mellitus (DM) and impaired glucose tolerance (IGT) are not uncommonly associated with hypertension. Fasting blood glucose level is still recognized as an indicator of DM. Methods: We studied 99 consecutive patients who were not known to be diabetic patients and with no cardiac history, who were attending our Hypertension Clinic for investigation and management of uncontrolled blood pressure (BP). Oral glucose tolerance test (GTT) was carried out and area under the curve for the GTT (AUC-glucose) was calculated. All patients underwent 24-h ambulatory BP monitoring. Results: The GTT was abnormal in 58 patients (58%), indicating IGT in 18, impaired fasting glucose in 16, and DM in 24. The fasting and 120-min glucose level and AUC-glucose in patients with DM on GTT was higher (P Ͻ .0001) than in those with IGT/IFG and in the latter was higher than those with normal GTT. Multiple regression analysis showed that abnormal GTT was independent of the following: level of clinic or ambulatory BP; presence
U
ndiagnosed diabetes mellitus (DM) and impaired glucose tolerance (IGT) remain a public health problem. The incidence of unrecognized DM and IGT in the general population varies between different places. In one study in the Isle of Ely in the United Kingdom, glucose tolerance tests (GTT) showed diabetic curve in 4.5% of a total of 1122 individuals and IGT in 16.7%. 1 On the other hand, in a study in Cremona, Italy, an incidence of unrecognized DM was found in 2.5% of men and 3.4% of women, and IGT in 7.7% in men compared with 8.9% in women. 2 Ethnicity may have its role in defining the prevalence of abnormal glucose metabolism. In a screening study in Coventry, England, the incidence of DM varied between 11.2% in Asian men and 8.9% in Asian women, as compared with 2.8% and 4.3% in white men and women respectively. 3 Hypertension is one of the most important contributors to cardiovascular diseases. It clusters with other cardiovascular risks such as abnormal glucose metabolism and hyperlipidemia with a hazard depending upon the number of these associated conditions present. 4 Hypertension accelerates the progression of diabetic complications. It was found that DM is more prevalent in patients who have one or more risk factors for cardiovascular disease. The Framingham study between 1970 and 1982 showed that 6.3% of established hypertensive subjects have DM compared with 4.3% of normotensive men and 2.1% of normotensive women. 5 The prevalence of DM or IGT has not yet been determined in the hypertensive population.
The oral GTT is the most accurate test that is currently available for diagnosing abnormal glucose metabolism. However, hospitals often limit its use to patients with glucose levels Ͼ6.0 mmol/L. For cost reasons, GTT is not widely used for general screening purposes.
We carried out this study to determine the prevalence of abnormalities of glucose tolerance, as demonstrated by the GTT, in subjects who were not known to have DM or histories of cardiac disease, and who had uncontrolled BP and were attending the Hypertension Clinic in our hospital.
Methods
A total of 111 consecutive patients attending the Hypertension Clinic at the Central Middlesex Hospital were recruited after referral by their general practitioners for the investigation and management of uncontrolled blood pressure (BP). Their age ranged between 33 and 82 years (median 60). When first seen, the 12 patients who were known to be diabetic were excluded. After a full history was taken and complete medical examination was performed, the remaining 99 patients who were not known to be diabetic underwent various basic biochemical tests, GTT, and ambulatory BP monitoring. Staff members performing the various tests did not have full knowledge of patients' BP recordings or treatment with drugs. Patients with history of ischemic heart disease, previous history of myocardial infarction or stroke, renal transplantation, evidence of renal impairment, or chronic liver disease, as well as those who were receiving steroids, were not included in the study.
Ambulatory BP recording was carried out using Reynolds monitors (Tracker 2 NIBP; Del Mar Reynolds Medical Ltd., Hertford, United Kingdom). The monitor was preprogrammed to make a recording of the BP every 30 min. Analysis of the results of the recording demonstrated average 24-h BP, average daytime BP (between 7 AM and 11 PM) and average night-time recording (between 11 PM and 7 AM). A nocturnal dip in BP was defined as a drop in nocturnal systolic or diastolic BP of Ն10% of the average daytime recording.
An oral GTT was carried out in the 99 subjects who were not known to be diabetic or to have symptoms of DM. After a minimum of 12-h overnight fast a blood sample was taken. The patient was then given 75 g glucose orally in water solution. Two more blood samples were drawn at 60 and 120 min after the glucose administration. Plasma glucose was measured by standard automated method of glucose oxidase, (Instrumentation Laboratories, United Kingdom). According to the World Health Organization criteria used, glucose tolerance results were classified as diabetic when the fasting plasma glucose level was Ͼ7.0 mmol/L or a 2-h level of Ն11.1 mmol/L. .6 Impaired fasting glucose was defined when fasting plasma glucose level was between 6.1 and Ͻ7.0mmol/L. Impaired glucose tolerance was defined as a fasting plasma glucose value Ͻ7.0mmol/L together with a 2-h level Ն7.8 mmol/L but Ͻ11.1 mmol/L. 6 Measurement of the area under the curve for the GTT (AUC-glucose) was carried out using Tai's formula. 7 
Statistical Analyses
Comparison of the different parameters between groups as shown in Tables 1 and 2 was made using the MannWhitney U test (between two individual groups) and the Kruskal-Wallis H test (among three groups). The 2 test was used to test between the groups for ethnic differences, numbers of patients with raised BP and those with a nocturnal dip in the BP, results of GTT, and individual drugs taken. Multiple regression analysis using the backward stepwise method was applied to test the relation between different parameters and the results of the GTT. A value of P Յ .05 was regarded as significant.
Results
Demographic features of the patients are listed in Table 1 . The GTT was abnormal in 58 patients (58%). Impaired glucose tolerance was diagnosed in 18 patients, impaired fasting glucose (IFG) in 16 patients, and a diabetic curve was found in 24 patients. Patients with DM were older than those with IGT or normal GTT. All groups were similar in regard to weight, gender, ethnicity, and smoking habit. Fasting glucose level was higher in patients with abnormal GTT than in those with normal GTT (Table 1) . Fasting plasma glucose level was normal in 48% of the patients with abnormal GTT, 18 patients with IGT, and 10 patients with diabetic GTT. Of 70 patients, 28 (40%) with normal fasting glucose level had abnormal GTT results. Fasting and 120-min plasma glucose levels as well as AUC-glucose were significantly higher in the diabetic patients than in patients with either IGT or IFG, which in turn were higher than in the euglycemic group (P Ͻ .0001). There was no significant difference between patients with normal GTT and those with abnormal GTT in the clinic BP reading or in the ambulatory recordings, either daytime or nighttime. As shown in Table 1 , there was also no difference in the number of patients who showed a nocturnal dip in the BP among the three groups.
Multiple regression analysis showed that neither the type of GTT abnormality nor its absence were related to age, ethnicity, gender, level of clinic BP or ambulatory BP, presence or absence of nocturnal BP dip, cholesterol level, smoking history, alcohol intake, coffee or tea consumption, type of drug taken for previous treatment for hypertension, or sodium or potassium levels. The 2-h plasma glucose level was linearly related to serum triglyceride level (r ϭ 0.4, P Ͻ .05). Triglyceride level was significantly higher in patients with abnormal GTT than those with normal GTT.
Our findings failed to show a relationship between GTT results and medications taken. Table 2 summarizes treatment medications in each group of patients. Of 99 patients (27%) who underwent GTT, 27 patients (27%) were not receiving any antihypertensive medications when first seen in the clinic and at the time of the tests. The
2 test failed to demonstrate a relationship between results of GTT and type of the medication taken, including diuretics and ␤-adrenergic blockers. Patients who were taking diuretics, diuretics and ␤-adrenergic blockers, or those who were not taking these drugs, did not differ significantly in their age, plasma level of glucose during GTT, or AUCglucose (Table 3 ). Multiple regression analysis on patients using diuretics, those who were using diuretics and ␤-adrenergic blockers, and those who were not taking diuretics and ␤-adrenergic blockers showed that the only determinants of the results of the GTT were the AUC-glucose and the 120-min plasma glucose level, which were not affected by any other variable shown in Table 1 , including age.
Discussion
Our study has demonstrated abnormalities of glucose metabolism in a significant proportion (58%) of the apparently nondiabetic patients without histories of cardiovascular disease who were referred to our local hospital hypertension clinic. The fasting plasma glucose level in 48% of these patients fell within the normal range. This finding was irrespective of the level of the clinic BP or the BP recorded on the 24-h monitor, whether during the day or the night. The results were also irrespective of whether the patients were nocturnal dippers in their BP. Our findings were also independent of patients' age, cholesterol or triglyceride level, type of antihypertensive medication taken before the first clinic visit, smoking or alcohol history, coffee or tea intake, or urea, creatinine, or electrolyte level.
Abnormalities of glucose metabolism including DM and IGT are recognized risk factors for cardiovascular morbidity and mortality. Diagnosing DM and IGT at an early stage is a prerequisite to establishing appropriate primary prevention strategies. On the other hand, screening for DM and IGT in the general population, among whom the prevalence of these conditions is significantly lower, is a difficult public health problem and is potentially very expensive, depending on the method used. Other than fasting plasma glucose determination, methods such as testing for the presence of glycosuria 1 h after a main meal has not proved to be effective. 8, 9 In a large multiethnic population study it was reported that a fasting plasma glucose level of 5.8 mmol/L was sensitive but nonspecific for diagnosing DM. 10 Definition of an optimal threshold was, however, found to be affected by gender, age, body mass index, ethnicity, and the presence of hypertension. 10 In the Isle of Ely study Diabetes Project, subjects with newly diagnosed elevated blood glucose had higher BP, cholesterol, triglyceride, and LDL cholesterol concentrations than those with normal glucose level.
1 Accordingly, such differences in BP level and in the demographic characteristics of individual patients may make the use of fasting glucose as a screening method inaccurate, with a low sensitivity in practical daily clinical settings, especially in hypertensive patients.
Although fasting plasma glucose level is often taken as the preferred method of diagnosing abnormalities of glucose metabolism, seriously abnormal glucose metabolism may be missed using this approach. In our study, relying on fasting plasma glucose alone would have failed to identify 40% of patients with an abnormal GTT. Additionally, none of our patients with diabetic GTT had a fasting glucose measurement of Ͼ6.9 mmol/L, the current World Health Organization criterion for diagnosis of DM. Our findings are in agreement with other reports that showed that 32% to 72% of patients with previously undiagnosed DM had a 2-h glucose level of Ն11.1 mmol/L with a fasting glucose value of Ͻ7 mmol/L. [11] [12] [13] Similarly, 54 -67% of subjects with IGT have a fasting glucose value Ͻ 6.1 mmol/L. [13] [14] [15] Furthermore, it has been argued that even if fasting glucose threshold is lowered to 5.5 mmol/L, the ability to detect DM will be in the region of 93% of all subjects diagnosed with DM on the basis of 2-h glucose value. 13 Additionally, the ability to diagnose IGT does not improve substantially even at this low threshold. 13 We therefore confirm other reports 14 that measuring fasting plasma glucose alone may misclassify as euglycemic a substantial number of subjects with abnormal GTT.
The risks of cardiovascular morbidity and mortality imposed by DM and elevated BP are additive. It has been postulated that essential hypertension is a state of insulin resistance because of the association found between these factors in subjects with normal body weight and normal glucose tolerance. 15 One of the reasons why the presence of DM in hypertensive individuals leads to more pronounced cardiovascular complications is reduced arterial compliance and increased peripheral resistance when compared with those in hypertensive persons without DM. 16 Because risks such as DM or IGT cluster with risks of hypertension, it is vitally important to make a proper diagnosis to identify such conditions. This has important implications for further management and decisions regarding appropriate therapies.
Although there are controversial reports regarding the ability of hyperinsulinemia to predict risks of development of cardiovascular disease, 17, 18 it is beyond doubt that insulin resistance is highly predictive of risks of coronary heart disease and stroke. 19 More interestingly, AUC-glucose was also a predictor of risk of coronary heart disease in the Helsinki Policemen Study. 19 In the current report we have shown that hypertensive individuals with preclinical DM or preclinical IGT or IFG and without cardiovascular history have significantly higher AUC-glucose than euglycemic hypertensive persons without cardiovascular histories. These individuals accordingly are at high risk for developing coronary heart disease and stroke in the future. Although other factors contribute to the definition of "insulin resistance" when clustered together (such as body mass index, waist to hip ratio, triglycerides, and insulin level 20 ) our three groups of patients had similar weight. Thus, although obesity has been associated with abnormal glucose metabolism, there is no indication in our study that weight could have been used to select a subgroup of patients with abnormal GTT. Accordingly, other mechanisms may play a different role in hypertensive subjects. Other features of metabolic syndromes, such as higher triglyceride levels, were found in both the DM and IGT/ IFG groups. For that reason, our subjects with DM and IGT/IFG remain at high risk.
Our goal is to identify and then to implement the right management strategy for IGT and DM in our hypertensive patients. Although a significant reduction in BP among diabetic hypertensive patients was associated with a reduction in DM-related morbidity and mortality, 21 the effect of the same measures in hypertensive patients with IGT needs to be elucidated. We noted that patients with IGT but with normal fasting blood glucose level are common in our population. If these patients were at risk, then by current criteria they are not appropriately managed by hypotensive agents and statins alone.
Identification of individuals with abnormal glucose metabolism is important in the general population, especially among hypertensive individuals, so that a preventive strategy can be established. Both IGT and IFG are associated not only with increased total and cardiovascular mortality but also with other cardiovascular risk factors such as hypertension and dyslipidemia. 22 Similarly, subjects with either IGT or IFG are at increased risk for developing DM. 23 It has been reported that a significant number of individuals with fasting glucose levels as low as 5.6 to 6.0 mmol/L progress to DM. 24 In all, 39% of normotensive subjects with fasting glucose between 6.1 and 6.9 mmol/L progressed to DM within 7 years. 22 It has also been reported that the risk of developing DM over 3 years was greater among middle-aged men with fasting plasma glucose levels Ͼ6.1 mmol/L than for men with lower levels. 25 Coronary heart disease-related mortality is elevated with a fasting plasma glucose level of 5.8 to 6.9 mmol/L within the same cohort. 25 Although other authors have shown that 20% of patients with IFG have DM, 26 none of our patients with IFG had a diabetic 2-h glucose level. This may be explained by the small number of patients with IFG (n ϭ 16) in our study. Additionally, the population used in the study were Native Americans, who have a high incidence of glucose intolerance compared with multiethnic group of our study population. 26 Equally important is the identification of patients with IGT. This is because individuals with IGT are at greater risk for cardiovascular death than are those with IFG. 27 The low sensitivity of fasting glucose level as a predictor of DM or IGT as diagnosed by a 2-h glucose level has been reported in a large sample study. 10 The risk of developing carotid artery stenosis is 3 times more in subjects with IGT than in subjects with normal GTT. 28 When compared with subjects with normal GTT, those with IFG or IGT tended to be more likely to have subclinical coronary atherosclerosis. 29 Furthermore, our subjects carried the additional vascular risk attributed to their hypertension. Although the incidence of DM (22%) 29 was similar to that (24%) in our study, we were able to identify further at-risk individuals (ie, with IGT and IFG) by performing GTT.
Our findings have several clinical implications. We have demonstrated the importance of assessing glucose metabolic status in hypertensive subjects attending a hospital hypertension clinic by GTT. A substantial number of such patients have DM, IFG, or IGT. Assessing patients by fasting glucose value results in misclassification of a substantial number of hypertensive individuals as euglycemic. Failure to identify abnormalities of glucose tolerance results in serious underestimation of these patients' risk for cardiovascular disease and denies patients primary preventative measures that are based on risk assessment. We believe that all patients referred to hypertension clinics who are believed to need treatment for elevated BP should be investigated by GTT. This strategy is vital for determining target BP and for choosing the appropriate medication for raised BP and any other modifiable risk factors. Identifying patients with IGT and IFG also enables appropriate management strategies to be put in place to prevent further progression to DM. For example, reductions in coronary events, in worsening of and development of new angina, in incidence of stroke, and in rate of development of heart failure have been reported in patients with DM when treated with ramipril. 30 -33 
